Genome-wide association study identifies three novel loci in Fuchs endothelial corneal dystrophy by Afshari, NA et al.
ARTICLE
Received 5 Jul 2016 | Accepted 6 Feb 2017 | Published 30 Mar 2017
Genome-wide association study identiﬁes three
novel loci in Fuchs endothelial corneal dystrophy
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The structure of the cornea is vital to its transparency, and dystrophies that disrupt corneal
organization are highly heritable. To understand the genetic aetiology of Fuchs endothelial
corneal dystrophy (FECD), the most prevalent corneal disorder requiring transplantation, we
conducted a genome-wide association study (GWAS) on 1,404 FECD cases and 2,564
controls of European ancestry, followed by replication and meta-analysis, for a total of 2,075
cases and 3,342 controls. We identify three novel loci meeting genome-wide signiﬁcance
(Po5 10 8): KANK4 rs79742895, LAMC1 rs3768617 and LINC00970/ATP1B1 rs1200114.
We also observe an overwhelming effect of the established TCF4 locus. Interestingly, we
detect differential sex-speciﬁc association at LAMC1, with greater risk in women, and TCF4,
with greater risk in men. Combining GWAS results with biological evidence we expand the
knowledge of common FECD loci from one to four, and provide a deeper understanding of the
underlying pathogenic basis of FECD.
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C
orneal diseases are one of the most common causes of
visual impairment and blindness worldwide, with Fuchs
endothelial corneal dystrophy (FECD) being the most
common indication for corneal transplantation in the United
States1. FECD is a bilateral, slowly progressive disorder of the
corneal endothelium affecting 4% of population above the age
of 40 years in the United States2,3. This debilitating disorder
becomes symptomatic in the ﬁfth or sixth decade of life4,5 and
affects two to four times more women than men3,6. Clinical
presentation of FECD varies, but often includes corneal oedema
that results in a loss of corneal clarity, painful episodes of
recurrent corneal erosions and severely impaired visual acuity.
Medical management is often inadequate requiring corneal
transplantation. Histopathological changes in FECD include loss
of endothelial cells, thickening of Descemet membrane (DM) due
to excessive accumulation of extracellular matrix, formation of
central excrescences on DM (corneal guttae) and subepithelial
bullae and scarring7. FECD likely arises during neural crest
differentiation8, but the reason for loss of functioning endothelial
cells is unknown.
FECD often clusters within families, with heritability estimated
atB39% (ref. 9). The understanding of genetics of FECD initially
focussed on genetic linkage, as a consequence of the observation
by Krachmer et al.5 that this disease showed a dominant mode of
inheritance in families. Linkage and ﬁne-mapping studies in
families identiﬁed rare point mutations in COL8A2 (ref. 10),
SLC4A11 (ref. 11) and TCF8 (ref. 12); these constituted the early
genetic discoveries of Fuchs dystrophy. Most recently, a genome-
wide association study (GWAS) including 280 cases and
410 controls in both discovery and replication samples found
common genetic variation in TCF4 to be associated with
Fuchs dystrophy, along with two other loci that did not reach
genome-wide signiﬁcance13. The association with TCF4 has been
replicated by multiple investigators, including our group14,15, and
a subsequent publication suggested that a trinucleotide repeat
expansion within intron 3 of the TCF4 gene is risk factor for this
disease16. Here, we report the discovery of three new loci
associated with FECD, KANK4 (KN motif- and ankyrin repeat
domain-containing protein 4), LAMC1 (laminin gamma-1) and
LINC009970/ATPB1 (Naþ , Kþ transporting ATPase, beta-1
polypeptide), and conﬁrm the strong effect of TCF4 variants in
our large samples of FECD cases and controls. Moreover, we
show evidence for sex-speciﬁc effects for associated markers at
TCF4 and LAMC1, and describe the expression of the four risk
loci in ocular tissues. The loci identiﬁed in this GWAS have not
previously been reported for any other corneal dystrophy. Their
discovery warrants further investigation into disease-causing
mechanisms, including the maintenance of corneal endothelium
integrity and ﬂuid transportation.
Results
GWAS and replication of associated regions. GWAS was
performed on a discovery data set of 3,968 unrelated subjects,
which include 1,404 cases and 685 controls selected from two
FECD genetic study groups9,15 and 1,879 controls from the Age-
Related Eye Disease Study (AREDS) Refractive Error Substudy17
(Supplementary Tables 1–3). We identiﬁed six regions containing
single-nucleotide polymorphisms (SNPs) with genome-wide
signiﬁcant associations (Po5 10 8 from logistic regression),
of which 18 SNPs were advanced to replication (Fig. 1, Table 1
and Supplementary Figs 1 and 2). We also observed modest
evidence for association at AGBL1 (P¼ 7.5 10 5) and
LOXHD1 (P¼ 3.4 10 4), two of seven genes previously
implicated in FECD through family-based and gene-targeted
studies (Supplementary Table 4).
Three independent data sets with a total of 671 FECD cases
and 778 controls served as replication (Supplementary Table 5).
Four out of six regions showed strong evidence (Po5 10 8
from meta-analysis) for association with FECD in the discovery
and replication cohorts (Table 1, Supplementary Table 6
and Supplementary Fig. 3). The previously identiﬁed locus at
TCF4 (refs 13–15,18–20), encoding the transcription factor
E2-2, remained the strongest association in both discovery and
replication cohorts (most signiﬁcant SNP rs784257; meta-
P¼ 2.5 10 200), with the largest effect sizes in both the
discovery (odds ratio (OR)¼ 5.77, 95% conﬁdence interval
(CI)¼ 5.05, 6.60) and replication (OR¼ 3.89, 95% CI¼ 3.30,
4.59) samples. Replication was also successful in three regions
on chromosome 1: intronic within the KANK4 gene (meta-
P¼ 1.2 10 14 at rs79742895), intergenic region between
LINC00970 and the ATP1B1 gene (LINC00970|ATP1B1, meta-
P¼ 9.9 10 19 at rs1022114) and intronic within the LAMC1
gene (meta-P¼ 6.9 10 16 at rs3768617). The discovery sample
was well powered (40.9) to detect association of the index
markers at these four loci with the observed effect sizes
(Supplementary Table 7).
Properties of index variants. The most signiﬁcant TCF4 SNP,
rs784257, explained 21.9% of the variation in FECD in the dis-
covery sample, whereas the top markers in the other three
replicated genome-wide signiﬁcant loci each explained between
0.9% and 1.5% of the variation in the discovery sample
(Supplementary Table 8). Strong linkage disequilibrium
(r2¼ 0.88) exists between rs784257 and the previously reported
variant rs613872, in the third intron of TCF4 (ref. 13). Both SNPs
are in moderate disequilibrium with the expanded form of the
CTG18.1 trinucleotide repeat in intron 2 of TCF4 (r2¼ 0.47),
consistent with the previously reported values of 0.65 and 0.31
between the triplet repeat and rs613872 in FECD cases and
controls, respectively21. The CTG18.1 repeat expansion is a
strongly inﬂuential variant with good biologic plausibility22,23,
but does not fully explain disease occurrence in all patients
because of the lack of penetrance in some families21.
Genetic risk scores were calculated for the discovery cohort
based on the most signiﬁcantly associated SNP from each of the
four replicated regions. The area under the curve (AUC) for
FECD cases versus controls was 0.782 (95% CI¼ 0.767, 0.797),
showing strong predictive value compared to other complex traits
analysed by GWAS24 (Fig. 2). Predictive value was primarily
through genotypes at rs784257 in TCF4 (AUC¼ 0.750; 95%
CI¼ 0.736–0.765); the AUC without rs784257 was substantially
smaller but still signiﬁcantly 40.5 (AUC¼ 0.606; 95%
CI¼ 0.587–0.624). We also found that adding the three non-
TCF4 SNPs to the model signiﬁcantly increased the AUC
(P¼ 7.7 10 18 by DeLong’s test25).
Pairwise SNP SNP interaction tests among the markers listed
in Table 1 revealed no signiﬁcant (Po0.05 from logistic
regression including an SNP SNP interaction term) interactions
between loci. The discovery data set was large enough to detect
an interaction risk ratio of 1.4–1.8 with at least 80% power
(Supplementary Table 9). Conditional analysis on the TCF4
marker rs784257 did not substantially alter the effect sizes of the
other loci (Supplementary Table 10). Moreover, a sensitivity
analysis using only FECD cases from the discovery cohort
conﬁrmed by histopathology (Supplementary Table 11) showed
no overall reduction in effect sizes (Supplementary Table 12 and
Supplementary Fig. 4), indicating that our classiﬁcation of
affected status is reliable.
From the sex-stratiﬁed analysis on the discovery cohort, we
identiﬁed that the risk-associated major allele G of LAMC1
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variant rs3768617 confers a signiﬁcantly greater elevated risk
of FECD on women (OR¼ 1.52, 95% CI¼ 1.32, 1.72) than
on men (OR¼ 1.16, 95% CI¼ 0.98, 1.34) (P value for hetero-
geneity, Phet¼ 0.013 by w2 test; Supplementary Table 13 and
Supplementary Figs 5 and 6), explaining 1.74% of the overall
FECD risk for women in the sample, but only 0.23% of the risk
for men. On the other hand, the TCF4 variant rs784257 shows
higher risk of FECD on men (OR¼ 7.56, 95% CI¼ 5.96, 9.57)
than women (OR¼ 5.06, 95% CI¼ 4.29, 5.96, Phet¼ 0.0063). Sex-
speciﬁc association analysis on the Flinders University replication
cohort supported these ﬁndings, whereas results from the other
two cohorts did not (Supplementary Fig. 7). Regardless, both
rs3768617 and rs784257 showed signiﬁcant sex heterogeneity of
effect in meta-analyses combining discovery and replication
samples (Supplementary Fig. 7). The discovery sample offered
adequate power (B0.8) to detect the SNP sex interaction effects
observed for these two markers with signiﬁcant P values
(Supplementary Table 14). Herein, we present the ﬁrst evidence
of genetic contribution to the sex-speciﬁc risk for FECD.
Functional signiﬁcance of major association results. To derive
functional insights regarding the genes nearest the most sig-
niﬁcant SNPs from GWAS, we examined several biologic sources
of information, including transcription factor, histone mark and
expression quantitative trait loci (eQTLs) reference maps from
public databases that did not include corneal tissue (HaploReg26;
http://www.broadinstitute.org/mammals/haploreg/haploreg.php).
Reasoning that similar regulatory features may be shared between
the corneal endothelium and other cell types of neural crest
origin, we placed greater emphasis if the evidence came from
these cell types, but used gene expression proﬁles from normal
corneal endothelium as a guide for interpretation. We then
examined, by immunohistochemistry (IHC), patterns of relevant
genes in corneal tissue sections from cases and controls using
antibodies directed against speciﬁc gene products.
Examining transcriptomic proﬁles from normal corneal tissue
and focussing on a 1-Mb interval centred on the best SNP for
each locus, we note that TCF4, ATP1B1 and LAMC1 are highly
expressed in corneal samples comprising only the corneal
endothelium and DM (Supplementary Data 1). LINC00970, the
lncRNA closest to ATP1B1, shows no expression, while KANK4
shows minimal expression. TCF4, a basic helix–loop–helix
transcription factor, was detected in the nucleus of residual
endothelial cells of Fuchs case samples by IHC (Supplementary
Fig. 8). No genotype data were available from the sample donors,
and, therefore, we could not explore the inﬂuence of associated
variants on gene expression in ocular tissue.
Our lead SNP in KANK4, rs79742895, was associated with
promoter and enhancer mark enrichment in multiple tissues
(Supplementary Data 2), conceivably altering motifs for tran-
scription factors, hypermethylated in cancer1 and Y in Yang1.
The cellular function of KANK4 is poorly understood, but
mutations in KANK proteins lead to steroid-resistant nephrotic
syndrome27. Modelling of mutations via knockdowns illustrate
that B50% of kank2 morphant zebraﬁsh develop periorbital
oedema and kidney disease, which the authors ascribe to
loss of kidney function. Knockdown analysis of the KANK3
orthologue in Caenorhabditis elegans suggests a role in cell-to-cell
contact and tissue integrity28. Distinct from TCF4, KANK4
immunostaining revealed that localization of KANK4 is mainly
within the endothelial cytoplasm in both control and FECD
samples (Supplementary Fig. 8). KANK family proteins may
have a role in the regulation of actin stress ﬁbres, which are
hypothesized to hold the endothelial cell nuclei in place through
cellular adhesion of the endothelial cytoplasmic layer29.
rs79742895, in KANK4, was also associated with an eQTL
for the LINE-1 containing transposase domain containing 1
(L1TD1) gene 23.84 kb distal to KANK4 (ref. 30). Similar to
KANK4, L1TD1 is only weakly expressed in the corneal
endothelium (Supplementary Data 1). L1TD1 is a RNA-binding
protein involved in preserving pluripotency of stem cells via post-
transcriptional regulation, showing high expression in pluripotent
cells31. Functions of moieties that interact with L1TD1 can be
divided into three categories: RNA post-transcriptional
modiﬁcation, protein synthesis and gene expression. Emani
et al.31 reported that LAMC1 is involved in protein synthesis
under control of L1TD1. No other variants with r2Z0.8 were
located in linkage disequilibrium with rs79742895 and identiﬁed
by HaploReg.
The strongest functional evidence for rs3768617 in LAMC1 is
with eQTLs. Eight entries with signiﬁcant eQTLs were found to
map within LAMC1 or LAMC2, the vast majority in brain or
nerve tissue (Supplementary Data 2). Thus, this variant, or others
in linkage disequilibrium, appear to self-regulate the expression
levels of LAMC1 and LAMC2, both of which have a key role as
cell adhesion proteins in basement membranes, such as DM32;
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Figure 1 | Results from GWAS for FECD. Negative log P values (vertical axis) from 8,680,745 SNPs are shown. The red horizontal line marks genome-wide
signiﬁcance (P¼ 5 108). Negative log P values are condensed above P¼ 10 12. Vertical grey lines are chromosome boundaries. The genomic control
parameter56 was 1.033, indicating adequate control of test statistic inﬂation from population stratiﬁcation (Supplementary Fig. 2).
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laminins are asymmetrically expressed on the endothelial side of
DM33. Knockouts of this gene cause failure of ureteric bud
development, or reduction in kidney size, with an insufﬁciency of
water transport postnatally34. An important feature of this
model is the absence of basement membranes in the kidney
early in development, and reduction in levels of integrin-a6 and
FGF2, key elements of cellular growth. A similar LAMC1-
knockout model in cardiomyocytes derived from human
embryonic stem cells also exhibited lack of proper basement
membrane formation, leading to inappropriate extracellular
matrix deposition between cells that upset electrical signal
conduction35. Analogous defects likely occur in the corneal
endothelium and DM in FECD. Strengthening this hypothesis,
IHC of control corneal endothelial samples pinpointed KANK4
and LAMC1 protein expression within the cytoplasm. In FECD
cases, a decline in the number of endothelial cells resulted
in concomitant decrease of KANK4 and LAMC1 positively
stained cells (Supplementary Fig. 8), which retained cytoplasmic
expression of the proteins.
rs1200114 maps to an intergenic region between ATP1B1 and
LINC00970, which does not show expression in the corneal
endothelium. Conversely, ATP1B1 shows high expression in
the endothelium (Supplementary Data 1). This SNP shows no
signiﬁcant eQTLs in GTEx, but does show strong enrichment for
enhancer and promoter marks, particularly in numerous brain
tissues (Supplementary Data 2). The b-subunit of the multimeric
Naþ ,Kþ -ATPase has a key function in structural integrity of the
protein, and its functional maturity. It is a regulator of ﬂuid
balance, ion transport and maintains the cellular homeostatic
equilibrium36. Lack of ATP1B1 may lead to hypertonicity within
the cornea and cause the corneal oedema seen in patients
suffering from FECD.
Recognizing that ATP1B1 represented our most signiﬁcant
GWAS signal after TCF4, we sought additional supporting
evidence at the gene expression level. Unbiased mining of
proteomic data by Poulsen et al.37 corroborated the expression of
LAMC1 and ATP1B1 in disease-relevant tissues. By IHC using
LAMC1 and ATP1B1 antibodies in three pairs of full-thickness
corneas from FECD cases and controls, we conﬁrmed expression of
these proteins in the corneal endothelium (Supplementary Fig. 9).
Discussion
We identiﬁed three novel loci, KANK4, LAMC1 and ATP1B1, for
FECD, and demonstrated cellular expression of TCF4. Our results
support a multifactorial model for disease aetiology with strong
predictive power (AUC¼ 0.78 from an oligogenic risk-score
model), although variants in TCF4 alone do a commendable
job of predicting risk in Caucasians. We conﬁrm the strong
association of variants such as rs613872 in TCF4, initially
discovered by Baratz et al.13, and extend these results by
demonstrating sex-speciﬁc effects. In contrast, we observed only
modest association at loci previously identiﬁed through family-
based and candidate-gene studies10–12,38–40.
Our data favour LAMC1 as increasing risk in women, whereas
TCF4 increases risk in men. Alleles at both loci are quite
common, and their precise role in mediating sex-speciﬁc risk
remains to be elucidated. Taken together, these results suggest
that these proteins have essential roles in the corneal endothelium;
for instance, water transport, appropriate basement membrane
maintenance, as well as tissue integrity and cell-to-cell contact.
Disruption of these activities may lead to pathogenic processes
characteristic of FECD. The primary function of the corneal
endothelium is to maintain a state of relative dehydration, with
hindrance of routine ﬂuid transport leading to corneal oedema.
We propose that all three genes regulate ﬂuid transport, with
ATP1B1 having the most obvious role as it encodes a subunit of
the sodium-potassium plasma membrane pump. LAMC1 also has
a role in normal basement membrane deposition, as shown in
knockout models of the kidney and cardiomyocytes, possibly
leading to thickening of the DM. Although functional data
supporting an effect of rs3768617 on LAMC1 expression exists in
GTEx, this database does not include the cornea. Limited data on
the function of KANK4means that its function can currently only
be inferred by analogy to its paralogues, KANK2 and KANK3, and
is suggestive of maintenance of cell-to-cell contact and tissue
integrity. In FECD, endothelial cells reduce in number and
change shape to maintain regular contact with each other and to
preserve the endothelial barrier to ﬂuid entry into the corneal
stroma41,42. Identiﬁcation of additional genetic risk factors adds
to our understanding of FECD, thus enabling development of
novel therapies for this disabling disease.
Table 1 | Major results from the FECD genome-wide association study.
Gene SNP Chr Pos All. Discovery cohort (n¼ 3,968) Replication Cohorts (n¼ 1,449) Combined (n¼5,417)
RAF case RAF ctrl OR (95% CI) Pdisc OR (95% CI) Prepl OR (95% CI) Pcombined Qp
KANK4 rs79742895 1 62,782,860 C/T 0.0889 0.0474 2.07 (1.69, 2.54) 2.5 10 12 2.18 (1.36, 3.50) 1.2 1003 2.09 (1.73, 2.52) 1.2 10 14 0.83
ATP1B1 rs1200114 1 169,060,489 G/A 0.4277 0.3411 1.43 (1.29, 1.57) 8.0 10 13 1.53 (1.30, 1.79) 1.7 1007 1.45 (1.34, 1.58) 9.9 10 19 0.48
LAMC1 rs3768617 1 183,092,500 A/G 0.3553 0.4214 0.75 (0.68, 0.82) 8.8 1009 0.62 (0.53, 0.72) 2.1 1009 0.71 (0.65, 0.77) 6.9 10 16 0.26
CFH rs2274700 1 196,682,947 T/C 0.4287 0.3709 1.31 (1.19, 1.44) 3.4 1008 1.08 (0.91, 1.27) 3.8 1001 1.25 (1.15, 1.36) 1.8 1007 0.097
SLC25A22 rs12223324 11 772,701 A/G 0.4826 0.5445 0.77 (0.70, 0.85) 2.1 1007 0.92 (0.79, 1.07) 2.7 1001 0.81 (0.75, 0.88) 7.3 1007 0.24
TCF4 rs784257 18 53,397,199 A/G 0.4779 0.1796 5.77 (5.05, 6.60) 3.1 10 146 3.89 (3.30, 4.59) 6.3 10 59 4.94 (4.45, 5.48) 2.5 10 200 0.0041
All., alleles with reference allele ﬁrst; CI, conﬁdence interval; Chr, chromosome; OR, odds ratio; Qp, P value from Cochran’s Q test for heterogeneity; Pos, hg37 physical map position; RAF case and RAF
ctrl, reference allele frequency in cases and controls, respectively.
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Figure 2 | ROC curves for FECD status. Curves are shown from genetic
risk scores based on all replicated loci (black), rs784257 in TCF4 only
(blue) and all loci except rs784257 (magenta).
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Methods
Samples and phenotypes. Informed consent was obtained from all participants, in
accordance with the Declaration of Helsinki, and all procedures were conducted after
approval from the Institutional Review Boards at all participating centres.
FECD study subjects in the discovery sample were recruited through the FECD
Genetics Multi-center Study, based at Case Western Reserve University, and at
Duke University Eye Center (DUEC)9,43. The phenotype criteria are listed in
Supplementary Table 1. The sample originally comprised 2,710 individuals, of
whom 2,089 (1,412 FECD cases and 677 controls) were included in association
analysis (Supplementary Table 2 and see below). In addition, we included 1,879
FECD control participants from the AREDS Refractive Error Substudy (dbGaP
accession phs000001.v3.p1), originally collected for an age-related macular
degeneration clinical trial, but subsequently included in a GWA study on refractive
error; these subjects had no age-related macular degeneration, previous cataract
surgery or evidence of corneal dystrophy17. Twenty-nine AREDS samples were
submitted to both studies by both groups to ensure that genotype clustering was
compatible between samples originally submitted by the AREDS group and those
by the FECD Multi-center study. Supplementary Table 3 summarizes the
characteristics of the discovery samples.
Severity of FECD was assessed in both discovery samples using a modiﬁed
Krachmer grading scale5 (Supplementary Table 2). Discovery samples had
undergone penetrating keratoplasty or Descemet stripping endothelial keratoplasty
in at least one eye, or had at least grade 3 FECD by the modiﬁed Krachmer scale in
at least one eye (although most individuals were symmetric). Because keratoplasty
is an unreliable indicator of FECD severity (228 of 1,254 cases (18.2%) with no
corneal oedema and a grade 4 or below)44, we conducted a sensitivity analysis
restricting the case deﬁnition to include only FECD cases with histopathological
veriﬁcation of severe FECD (see below). Based on discussions between investigators
at all three centres, the following inclusion criteria for controls have been
established to determine subject eligibility from each ascertainment site: (1) 60
years of age or older, (2) normal cornea by slit-lamp biomicroscopy with no
epithelial, stromal or endothelial abnormalities with the exceptions of (a) arcus
senilis and Vogt’s limbal girdle; (b) cornea scar from infection or penetrating
trauma; (c) pterygium; inactive superﬁcial vascularization of the epithelium or
subepithelial zone; (3) previous cataract, glaucoma or retina–vitreous surgery was
allowed, as long as the preoperative record indicated no evidence by slit-lamp
examination of guttae or FECD and postoperative exam also showed no evidence;
and (4) previous intraocular laser surgery (such as iridotomy, trabeculoplasty or
pan retinal photocoagulation) was allowed with same caveats as intraocular
surgery.
A total of 1,449 samples (671 FECD cases and 778 controls) from three study
centres were included in the replication phase (Supplementary Table 5). Three
centres participated: the University of Iowa (Iowa City, IA, USA), Flinders
University (Adelaide, SA, Australia) and Johns Hopkins (JHU) (Baltimore, MD,
USA). All three centres required controls to be 50 years or older, and cases to have
Krachmer grade 1 (ref. 5) (modiﬁed Krachmer grade 2) FECD or higher
(Supplementary Table 2). We used the grading scheme provided by the replication
cohorts and converted it to grades equivalent to the scale used for the discovery
cohort. Detailed below are the grading criteria used by each cohort. Because of the
scarcity of available replication samples, the case deﬁnition is in general less strict
than for the discovery sample.
The University of Iowa cohort comprised 113 patients with FECD and 113
control subjects, all of European ancestry. All participants underwent detailed
ophthalmic evaluation that included slit-lamp biomicroscopy. Patients were
considered to have FECD if they had more than 12 central guttae or if they had
histopathologic conﬁrmation following corneal transplantation (keratoplasty) for
corneal oedema45. Control subjects were examined by a board-certiﬁed
ophthalmologist and did not have signs of FECD. A sample of B10ml blood was
collected from each study participant.
The Flinders University cohort comprised 190 patients with FECD.
Additionally, genomic DNA from 282 unrelated, unaffected South Australian
residents aged over 50 years, recruited previously for use as controls in ocular
genetic studies in our laboratory, was available for this study46–48.
The cases were Caucasian Australian patients diagnosed with modiﬁed
Krachmer scale grade 2 or above FECD who were recruited by ophthalmologists at
the Flinders Eye Clinic (Adelaide, SA, Australia) and the Royal Victorian Eye and
Ear Hospital (Melbourne, Victoria, Australia). Venous blood samples were
collected from 190 patients and genomic DNA extracted using QIAamp DNA
Blood Maxi Kit (Qiagen, Doncaster, Victoria, Australia) according to the
manufacturer’s protocol.
This study was approved by the Human Research Ethics Committees of the
Flinders Medical Centre/Flinders University of South Australia (Adelaide, SA,
Australia), and the Royal Victorian Eye and Ear Hospital. The research was
conducted in accordance with the National Health and Medical Research Council,
Australia guidelines.
The JHU cohort consisted of 368 Caucasian FECD cases and 380 ethnically
matched control subjects. All participants underwent a detailed ophthalmic
evaluation that included slit-lamp biomicroscopy. Affectation status and disease
severity were determined with the Krachmer scale5. Positive disease status was
indicated if the patient had a minimum modiﬁed Fuchs Krachmer grading score of
2 in at least one eye. The inclusion criteria for control subjects consisted of a
minimum age of 58 years and no signs or symptoms of FECD by slit-lamp
biomicroscopy. A 10-ml blood sample was collected from each study participant.
DNA was extracted using the Gentra Puregene Blood Kit (Qiagen, Santa Clara,
CA, USA).
Genotyping. Genotyping for the discovery samples was performed on the Illumina
HumanOmni2.5-4v1_H array at the Center for Inherited Disease Research (CIDR,
Baltimore, MD, USA). DNA samples on 96-well plates were balanced by FECD
status, collection site (Case Western Reserve University multi-center versus DUEC)
and sex.
A total of 2,841 FECD case–control samples, including duplicates, were
submitted for genotyping, of which 2,818 passed initial genotyping QC by CIDR.
The 1,922 AREDS control DNA samples, including 29 cross-study duplicate pairs
and 10 internal duplicate pairs, were processed separately at CIDR, but genotype
calling was performed with both sets together.
Eighteen SNPs were chosen for follow-up based on the genetic structure and
annotation information for the most signiﬁcant results from the Omni2.5M and
imputed GWAS within each region yielding Po5 10 8 for association for at
least one marker. The LD structure was characterized, using genotype data from
our FECD controls only, among the ﬁve SNPs with the most signiﬁcant
associations from the Omni2.5M data, and at least ﬁve SNPs from the imputed
data. From each region we chose two or more SNPs for replication: the most
signiﬁcant SNP plus one or more additional SNPs and, where available, highly
signiﬁcant exonic variants. Follow-up SNPs were chosen to minimize LD within
association peaks; SNPs within coding regions were chosen preferentially. Samples
were genotyped for 18 SNPs in or near KANK4 (rs12082238, rs12058486,
rs79742895), ATP1B1 (rs1200114, rs1200115), LAMC1 (rs2296292, rs3768617,
rs1413386, rs20560, rs20561), CFH (rs2274700, rs1329428), SLC25A22
(rs12223324, in PDDC1; rs4963153; rs1138714, in PNPLA2) and TCF4
(rs72932713, rs11659764, rs784257). The well-characterized TCF4 SNP rs613872
was not speciﬁcally selected for follow-up, but genotype data were available for the
SNP in the Flinders University sample. rs2296292 and rs20560 in LAMC1 were
chosen speciﬁcally because they were coding variants (A592A and R1376R,
respectively).
For the University of Iowa replication sample, DNA was extracted using the
Gentra Puregene Blood Kit (Qiagen, USA). Samples were submitted to LGC
Genomics (Petaluma, CA, USA) for genotyping using the KASPar assay, an end-
point polymerase chain reaction (PCR) assay using two competitive, allele-speciﬁc
forward primers and a common reverse primer. The average call rate over 17 assays
was 98.5%; rs2274700 failed to genotype.
For the Flinders University sample, genotyping data for the replication SNPs
were obtained for 190 FECD cases and 282 unaffected controls. All the SNPs were
genotyped in cases and controls using iPLEX GOLD chemistry (Sequenom,
Herston, QLD, Australia) on a MassARRAY Compact Spectrometer (Sequenom).
For genotyping of the Johns Hopkins University sample, the PCR was
performed in 5-ml volumes containing 10 ng genomic DNA, 2.5 ml SNP genotyping
master mix (TaqMan; Applied Biosystems, Foster City, CA, USA) and 0.125 ml
genotyping assay mix (TaqMan; Applied Biosystems). Reactions for all nine SNPs
were ampliﬁed independently in a thermocycler (9700; Applied Biosystems). The
cycling parameters consisted of 2-min incubation at 50 C and denaturation at
95 C for 10min, followed by 40 cycles of 10 s at 95 C and 1-min elongation at
72 C with a ﬁnal 10-min extension at 72 C. Ampliﬁed products were analysed for
the enrichment of speciﬁc alleles (ABI 7900HT Sequence Detection System;
Applied Biosystems).
We assayed the CTG18.1 repeat in intron 2 of TCF4 (refs 16,21,49) on a
subsample of 664 individuals from the discovery cohort by classifying repeats as
‘unexpanded’ (r40 copies of the repeat) and ‘expanded’ (440 copies)49. An initial
analysis was performed using a short tandem repeat assay21 by amplifying the
triucleotide repeat with primers 50-FAM-AATCCAAACCGCCTTCCAAGT-30 and
50-AATCCAAACCGCCTTCCAAGT-30 followed by sizing of PCR products by
capillary electrophoresis on an Applied Biosystems 3730 Genomic Analyser with
LIZ500 size standards21. Samples not showing evidence of two distinct alleles were
further analysed using a repeat-primed PCR assay21 incorporating an internal
primer 50-TACGCATCCCAGTTTGAGACGCAGCAGCAGCAGCAG-30 and
downstream primer 50-TACGCATCCCAGTTTGAGACG-30 (ref. 21) to check for
an expanded allele not detected by the short tandem repeat assay.
GWAS quality control. Genotype data were subject to intensive quality control by
the Quality Assurance/Quality Control analysis team at the University of
Washington Genetics Coordinating Center. Genotype concordance between
duplicate samples was high; the median discordance rate over 102 duplicate pairs
was 1.5 10 4. All samples passing quality control had call rates above 98%, and
the median call rate was 99.75%.
Relatedness between pairs of samples was estimated by means of the method-
of-moments approach50 implemented in the R package SNPRelate, on a subset of
124,583 autosomal SNPs in low linkage disequilibrium. A total of 15 samples were
omitted on account of unresolved identity issues, including disagreement of
annotated and genetic sex and of unexpected and unresolvable relationships.
Samples were classiﬁed as ‘related’ if their estimated kinship coefﬁcient was41/32
(equivalent to half the expected value for ﬁrst cousins). Association analysis
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included a total of 2,089 unique, unrelated samples of European descent from the
FECD Multi-center and DUEC samples that met the consortium criteria for FECD
case or control status.
Genetic sex was determined by means of X-chromosome heterozygosity and the
mean ﬂuorescence intensity of the X and Y chromosomes.
Chromosomal anomalies, including subchromosomal aneuploidy and mosaic
uniparental disomy, were detected using circular binary segmentation on B allele
frequencies or runs of homozygosity51. Anomalies 45 megabasepairs (Mb) in
length and entire chromosomes carrying 410Mb of anomalies were annotated.
Genotypes within these regions from the individuals carrying the anomalies were
omitted from association analyses. Anomalies of the X chromosome were
annotated but not ﬁltered.
Ancestry was estimated by means of principal components analysis (PCA) by
the approach of Patterson et al.52 as implemented in the R SNPRelate package.
PCA was initially performed on founder individuals using a subset of 133,530
autosomal SNPs pruned for linkage disequilibrium. Principal components were
determined for family members by the method of Zhu et al.53 Nine individuals of
putative European descent with outlying values for the ﬁrst two principal
components were omitted from association analysis.
Genotypes were initially obtained on 2,443,177 SNPs, of which 2,416,694 passed
CIDR technical ﬁlters. SNPs were excluded under the following quality control
ﬁlters: minor allele frequency¼ 0 in the sample; cluster separationo0.2; missing
rateZ2%; more than one discordant call among 158 study duplicates, including
27 HapMap sample pairs; any discordant calls within the FECD Multi-center9 and
AREDS17 cross-study duplicates; more than one Mendelian incompatibility; a
P value of o10 4 from an exact test of Hardy–Weinberg proportions; sex
difference in allele frequencyZ0.2; and sex difference in heterozygosity40.3.
A total of 2,111,249 SNPs passed all quality ﬁlters, including 1,449,159 with minor
allele frequencyZ0.02.
Imputation. Imputation of untyped variants in the 1000 Genomes Phase 1
reference panel, version 3, on all study samples passing quality control ﬁlters
was carried out at the University of Washington Genetics Coordinating Center.
Prephasing of 1,587,835 autosomal and non-pseudoautosomal, X-linked SNPs
overlapping with the reference panel was conducted by means of SHAPEIT2
(ref. 54) with 200 conditioning states. Imputation was performed over 5-Mb
segments with a 500-kb buffer using IMPUTE2 (ref. 55), based on a cosmopolitan
reference panel of all 1,092 samples from the Phase 1 integrated variant set.
Imputed genotypes within chromosomal anomalies (see Sample Quality Control,
above) were marked as missing in the ﬁnal output. Imputation was restricted to
SNPs with at least two copies of the minor allele within the pooled European
continental group; all indels and structural variants were excluded. Imputation
yielded 12,660,865 SNPs, including 354,144 X-linked SNPs.
Statistical analysis. Association between FECD status and 1,449,159 genetic
markers from the Omni2.5 panel was tested using logistic regression as imple-
mented in the R GWAStools package, including age, sex and the ﬁrst six principal
components from the PCA as covariates, using an additive inheritance model in the
number of alleles coded ‘A’ by Illumina (not necessarily the minor allele). Sig-
niﬁcance of association was measured using a Wald test. In testing X-linked SNPs,
male genotypes were coded as 0 and 2 (for BY and AY, respectively). The overall
genomic control parameter l (ref. 56) was 1.018. Because l-values below 1.05 are
generally considered not signiﬁcantly 41, no adjustment for genomic control was
performed.
Association testing was also performed on 8,680,745 imputed SNPs with
IMPUTE2 information quality metrics40.5 using the same statistical model. Here,
the genetic predictor was the dosage of the minor allele. The values of l over all
SNPs and omitting the TCF4 region were 1.033 and 1.028, respectively
(Supplementary Fig. 2).
We conducted subset analyses by (1) stratifying the sample by sex, and (2)
restricting the FECD cases to those conﬁrmed by histopathological examination
(n¼ 787), comparing to all controls (Supplementary Table 3). Association tests
were run by the same logistic regression model as described above, except that sex
was not included as a covariate in the sex-stratiﬁed analyses. Both genotyped and
imputed markers were analysed. Evidence for heterogeneity between men and
women was assessed by a w2 goodness-of-ﬁt test comparing normalized sex-speciﬁc
effect estimates with the pooled estimate57.
Genotypes from the replication samples were analysed by sample using
PLINK50 or R. w2 and Fisher’s exact tests were conducted to assess allelic and
genotypic associations. Allele frequencies in FECD cases and controls were
compared using Fisher’s exact test. Meta-analysis over three replication samples
(Supplementary Table 6) was performed by the inverse-variance weighting method,
from log ORs and 95% CIs estimated by the OR function in the R package
EpiTools. Because genome-wide marker data were unavailable for the replication
samples, we did not adjust for population structure by means of PCs.
A genetic risk metric was constructed from genotypes of the discovery sample
only at the most signiﬁcantly associated SNP at each of the six candidate gene
regions (Fig. 1), coded so that the effect allele was the risk-conferring allele,
summing the product of the number of risk alleles at each locus with the log of the
OR for the discovery cohort as listed in Table 1. The area under the curve (AUC)
and its 95% conﬁdence interval was calculated, and AUCs of different receiver
operating characteristic (ROC) curves were compared, using the R package pROC.
Sex-speciﬁc genetic risk scores were calculated by the same procedure, using effect
estimates derived from Supplementary Table 13.
Pairwise SNP:SNP interactions were tested among pairs of SNPs from Fig. 1 by
including two genotypes and an interaction term in the association model for the
discovery sample.
Gene expression and IHC. Surgical specimens of corneal endothelium and Des-
cemet’s membrane (CEþDM) complex were obtained from patients undergoing
keratoplasty because of advanced FECD and placed directly into RNAlater Solution
(Life Technologies, Mulgrave, VIC, Australia). The RNA from these tissues was
used for sequencing. Equivalent control specimens were obtained through the Eye
Bank of South Australia (Flinders Medical Centre, Adelaide, SA, Australia). The
specimens were placed in RNAlater Solution immediately after surgery or
dissection, and stored at 4 C for at least two days. Then RNAlater solution was
removed and the specimen stored at  80 C for later gene expression analysis.
Normal, eye-bank-derived, post-mortem corneas in Optisol GS from three
unaffected donors were obtained for gene expression analysis from Eversight Ohio
(Cleveland, OH, USA). The storage solution was discarded and tissues were placed
into RNAlater Solution and frozen on receipt. For each of the six loci from the
initial GWAS, the set of GENCODE genes (accessed through Ensembl Biomart,
http://www.ensembl.org) within and overlapping an interval of 1Mb centred on
the most signiﬁcant marker was included in the analysis. RNA was isolated using
the RNeasy Plus Kit (Qiagen, USA) according to the manufacturer’s protocol. RNA
was quantiﬁed using Qubit Picogreen ﬂuorescent assay (Life Technologies,
Carlsbad, CA, USA) and RNA integrity was checked with the Bio-Rad Experian/
Agilent Bio-analyser. Samples passing initial quality control were subject to rRNA
depletion with RiboZero Gold (Epicentre, San Diego, CA, USA) as per the
manufacturer’s instructions. rRNA-depleted fractions were used as input for library
preparation using ScriptSeq Gold Low Input Library Preparation Kit (Epicentre).
All libraries were quantiﬁed using the Qubit Picogreen ﬂuorescent Assay (Life
Technologies) and analysed with the Bio-Rad Experion system. The libraries were
further quantiﬁed with quantitative PCR using the KAPA Library Quantiﬁcation
Kit (KapaBiosystems, Wilmington, MA, USA). Sequencing was performed for
100 bp paired-end on the Illumina HiSeq 2500. The reads were mapped to the
reference human genome (hg38) using tophat (https://ccb.jhu.edu/software/tophat/
index.shtml). Read counts were performed for features in the GenCode version 21
database using htseq-count (http://www-huber.embl.de/users/anders/HTSeq/doc/
count.html). The expression level was normalized for each gene feature by
calculating reads per kilobase per million reads. We deﬁned ‘high expression’ as
410 reads per kilobase per million reads averaged over the three replicates.
For the primary immunohistochemical analysis, formalin-ﬁxed, parafﬁn-
embedded sections, 4–5 mm thick, of ﬁve FECD-affected and ﬁve normal corneas
were used. Immunohistochemical labelling on sections of affected and normal
corneas was performed as follows20,58. Primary antibodies were applied to each
section and incubated for 1.5 h in a chamber at 37 C. The dilutions were as
follows: ATP1B1 (LifeSpan BioSciences; LS-B235), 1:1,000; LAMC1 (LifeSpan
BioSciences; LS-B7354), 1:50; TCF4 (LifeSpan BioSciences; LS-B1570), 1:200;
KANK4 (Abcam; ab121410), 1:100. We used goat anti-rabbit horseradish
peroxidase (Abcam; ab6721) diluted 1:400 and goat anti-mouse horseradish
peroxidase (Fisher Scientiﬁc; PI31430) diluted 1:200 as the secondary antibodies.
Sections were processed with DAB Quanto (Thermo Fisher Scientiﬁc; TA-060-
QHDX), were counterstained with haematoxylin and were mounted in Cytoseal
XYL (Thermo Scientiﬁc, 8312-4). Images were captured on an Olympus BH-2
microscope (Olympus, Tokyo, Japan) ﬁtted with a Canon EOS6D 20.2 Megapixel
Digital Camera (Canon, Tokyo, Japan) using DSLR Remote Pro Imaging Software
(Breeze Systems, Surrey, UK).
Labelling on sections of affected and normal corneas for conﬁrmatory
immunohistochemical analysis was performed as above20, but without any antigen
retrieval. Sections were hybridized with the mouse anti-human ATP1B1 (clone
M17-P5-F11, catalogue no. PIEMA3-930, Thermo Scientiﬁc Pierce, supplied by
SABiosciences; 1:1,000 dilution) or rat anti-human LAMC1 (catalogue no.
AB80580, Sapphire Bioscience, Waterloo, NSW, Australia; 1:50 dilution)
monoclonal antibody (1:50) at 4 C overnight. This was followed by hybridization
with the NovoLink Polymer complex reagent (Leica Microsystems, Bannockburn,
IL, USA). Primary antibody binding was detected with Liquid DABþ substrate
Chromogen System (K3468; Dako Australia). Sections were counterstained with
haematoxylin and mounted in DePeX (Merck KGaA, Darmstadt, Germany).
Labelling was imaged on an Olympus BX50 microscope ﬁtted with QImaging
Micropublisher RTV 5 Megapixel Digital Camera using QCapture Imaging
Software (Olympus)20.
Web resources. Software:
GWASTools: http://www.bioconductor.org/packages/devel/bioc/html/
GWASTools.html
SNPRelate: http://cran.r-project.org/web/packages/SNPRelate/index.html
PLINK: http://pngu.mgh.harvard.edu/Bpurcell/plink/index.shtml
IMPUTE2: https://mathgen.stats.ox.ac.uk/impute/impute_v2.html
SHAPEIT: https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/
shapeit.html
EpiTools: http://medepi.com/epitools
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Data availability. We have deposited all genotype data supporting our ﬁndings
from the discovery cohort in the Database of Genotypes and Phenotypes (dbGaP),
with accession code phs000421.v1.p1. Other data that support our ﬁndings are
available from the authors by request; see author contributions and their published
references for speciﬁc data sets.
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